Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Harvey Capital Management Inc.

Harvey Capital Management Inc. decreased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 185,435 shares of the biopharmaceutical company’s stock after selling 425 shares during the period. Halozyme Therapeutics comprises about 2.1% of Harvey Capital Management Inc.’s investment portfolio, making the stock its 12th biggest holding. Harvey Capital Management Inc. owned about 0.15% of Halozyme Therapeutics worth $8,866,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Heck Capital Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $29,000. GAMMA Investing LLC boosted its holdings in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares during the period. Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics during the third quarter worth $57,000. FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth about $65,000. Finally, CWM LLC boosted its holdings in shares of Halozyme Therapeutics by 77.5% in the 3rd quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 668 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $57.33 on Wednesday. Halozyme Therapeutics, Inc. has a 52-week low of $34.36 and a 52-week high of $65.53. The firm has a market capitalization of $7.29 billion, a PE ratio of 18.98, a P/E/G ratio of 0.44 and a beta of 1.25. The firm has a 50-day moving average price of $51.90 and a 200 day moving average price of $54.42. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Analysts Set New Price Targets

A number of brokerages have issued reports on HALO. JMP Securities raised their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. Piper Sandler increased their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Wells Fargo & Company lowered their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $60.89.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.